Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Clinical journal of the American Society of Nephrology : CJASN - 1 Mar 2013

Bunch Donna O'Dell, McGregor JulieAnne G, Khandoobhai Nirmal B, Aybar Lydia T, Burkart Madelyn E, Hu Yichun, Hogan Susan L, Poulton Caroline J, Berg Elisabeth A, Falk Ronald J, Nachman Patrick H

Abstract excerpt

BACKGROUND AND OBJECTIVES: B cell significance in ANCA disease pathogenesis is underscored by the finding that ANCA alone can cause disease in mouse models and by the effectiveness of rituximab as therapy in ANCA-small vessel vasculitis (ANCA-SVV). To avoid infections and adverse events from ther...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Share to Antibodies, Monoclonal, Murine-Derived

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD5 Antigens

Share to Immunophenotyping

Share to Immunosuppressive Agents

Share to Recurrence

Share to Remission Induction

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 23293123
DOI: 10.2215/CJN.03950412
PMCID: PMC3586963

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23293123-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.PMID 23293123Read ↗

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiationSemantic proximity Read ↗

Longitudinal monitoring of circulating immune cell phenotypes in anti-neutrophil cytoplasmic antibody-associated vasculitis.Semantic proximity Read ↗

Classification of ANCA-associated vasculitis: differences based on ANCA specificity and clinicopathologic phenotype.Semantic proximity Read ↗

Altered B cells homeostasis in child-onset immunoglobulin A vasculitisSemantic proximity Read ↗

Antineutrophil cytoplasm antibody-associated vasculitis: recent developments.Semantic proximity Read ↗

B Cell Subsets and Cellular Signatures and Disease Relapse in Lupus Nephritis.Semantic proximity Read ↗

Autoantibodies towards HFE and SYT5 in anti-neutrophil cytoplasm antibody-associated vasculitis relapseSemantic proximity Read ↗

Targeting NF-κB signaling in B cells as a potential new treatment modality for ANCA-associated vasculitisSemantic proximity Read ↗

B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.Semantic proximity Read ↗

New insights into clinical spectrum of antineutrophil cytoplasmic autoantibody associated disease.Semantic proximity Read ↗

Impact of MEFV Mutations on Inflammatory Activity and Long-Term Relapse in Pediatric IgA VasculitisSemantic proximity Read ↗

Antineutrophil cytoplasmic antibodies – their role in pathogenesis, diagnosis and treatment monitoring of ANCA-associated vasculitisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.